Haleon posts tepid quarterly result


Revenues stood at £2.92bil (US$3.64bil) for the quarter ended March 31. — Reuters

NEW YORK: Consumer healthcare company Haleon has reported first-quarter revenue slightly below market estimates, as volumes declined due to retailer destocking in the United States and cooling demand for some of its medicines after a surge last year.

The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil’s sales in Canada, following a surge in demand last year.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Trading ideas: NuEnergy, Nexgram, PLB Engineering, Sapura Industrial, Borneo Oil
PETRONAS seals LNG supply deal with CNOOC
SIB disposes of Seremban land for RM25mil
Utility contracts set to drive Steel Hawk earnings
Nexgram focuses on core operations
Perak Transit eyes growth from terminal expansion
Borneo Oil’s associate seeks Nasdaq listing
Nam Cheong nets US$20.5mil in vessel sale
Trive Property to bank on its rental income
Fruit and vegetable exports rebound

Others Also Read